Status:
TERMINATED
Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Glostrup University Hospital, Copenhagen
Conditions:
Schizophrenia
Cognitive Deficits
Eligibility:
MALE
18-60 years
Phase:
EARLY_PHASE1
Brief Summary
Phosphodiesterase (PDE) inhibitors represent a new group of potential antipsychotic compounds currently under development. One of these is papaverine, an inhibitor of the PDE 10 family. The class of P...
Detailed Description
The study has a double blind, balanced crossover design. Randomized, half of the subjects will be given Papaverine (PDE10 inhibitor, 300 mg orally) in the first session followed by placebo in the seco...
Eligibility Criteria
Inclusion
- Diagnosed Schizophrenia (WHO ICD 10)
- Treatment stable (no regulation in medicine for 6 weeks prior)
- Mono antipsychotic treatment
- No regular Antidepressants (PN accepted)
- No regular Benzodiazepines (PN accepted)
Exclusion
- Dependence syndrome
- Severe physical illness
- MRI incompatible, non removable objects above shoulders
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01813955
Start Date
June 1 2011
End Date
June 1 2013
Last Update
May 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glostrup psychiatric center
Glostrup Municipality, Denmark, 2600